70 related articles for article (PubMed ID: 7431726)
1. [Experimental studies on the use of an immunoadjuvant (beta-1, 3 glucan) to prevent relapse after termination of chemotherapy in mouse model (author's transl)].
Kondo E; Kanai K
Kekkaku; 1980 Sep; 55(9):411-4. PubMed ID: 7431726
[No Abstract] [Full Text] [Related]
2. [beta-1, 3 glucan as an immunopotentiator against experimental tuberculous infection in mice (author's transl)].
Kanai K; Kondo E
Kekkaku; 1980 Aug; 55(8):371-4. PubMed ID: 7420811
[No Abstract] [Full Text] [Related]
3. Anthrax-protective effects of yeast beta 1,3 glucans.
Kournikakis B; Mandeville R; Brousseau P; Ostroff G
MedGenMed; 2003 Mar; 5(1):1. PubMed ID: 12827062
[TBL] [Abstract][Full Text] [Related]
4. [Beta-1,3-glucan and other immunomodulators in experimental leprosy infection in mice].
Delville J; Jacques PJ
Acta Leprol; 1979; (76-77):273-81. PubMed ID: 121844
[No Abstract] [Full Text] [Related]
5. Application of beta-1,3-glucan to prevent shipping fever in imported heifers.
Pedroso M
Arch Med Res; 1994; 25(2):181. PubMed ID: 7919809
[TBL] [Abstract][Full Text] [Related]
6. Use of glucan and other immunopharmacological agents in the prevention and treatment of acute radiation injuries.
Patchen ML; Chirigos MA; Brook I
Fundam Appl Toxicol; 1988 Nov; 11(4):573-4. PubMed ID: 3229582
[No Abstract] [Full Text] [Related]
7. [Further study of immunopotentiation in experimental antiblastic therapy by inactivated yeasts and glucan].
Delfina Pesce C; Boccanera M; Marconi P; Bistoni F; Cenci E; Tissi L; Cassone A
Ann Ist Super Sanita; 1982; 18(3):509-12. PubMed ID: 7187836
[No Abstract] [Full Text] [Related]
8. Immunomodulation of protozoan diseases. Potential of glucan as an adjuvant.
Cook JA; Runey GL; Holbrook TW
Surv Immunol Res; 1983; 2(3):243-5. PubMed ID: 6675146
[No Abstract] [Full Text] [Related]
9. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan).
de Felippe Júnior J; da Rocha e Silva Júnior M; Maciel FM; Soares Ade M; Mendes NF
Surg Gynecol Obstet; 1993 Oct; 177(4):383-8. PubMed ID: 8211583
[TBL] [Abstract][Full Text] [Related]
10. Controversies on the prevention of insulin-dependent diabetes mellitus by immunomodulation: lessons from NOD mice treated with beta-1,6;1,3-D-glucan and rhIGF-I.
Kida K; Kaino Y; Ito T; Hirai H
J Pediatr Endocrinol Metab; 1998 Apr; 11 Suppl 2():327-33. PubMed ID: 9642663
[No Abstract] [Full Text] [Related]
11. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.
Cheung NK; Modak S; Vickers A; Knuckles B
Cancer Immunol Immunother; 2002 Nov; 51(10):557-64. PubMed ID: 12384807
[TBL] [Abstract][Full Text] [Related]
12. Earlier methods of antibiotics administered prophylactically perioperatively.
Lord JW
Ann Surg; 1995 Nov; 222(5):689-90. PubMed ID: 7487219
[No Abstract] [Full Text] [Related]
13. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
14. Immunopharmacological studies of beta-1,3-glucan.
Ríos-Hernández M; Dos-Santos NJ; Silvia-Cardoso ; Bello-Gárciga JL; Pedroso M
Arch Med Res; 1994; 25(2):179-80. PubMed ID: 7919808
[TBL] [Abstract][Full Text] [Related]
15. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor.
Patchen ML; Liang J; Vaudrain T; Martin T; Melican D; Zhong S; Stewart M; Quesenberry PJ
Stem Cells; 1998; 16(3):208-17. PubMed ID: 9617896
[TBL] [Abstract][Full Text] [Related]
17. Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy.
Buccheri S; Reljic R; Caccamo N; Meraviglia S; Ivanyi J; Salerno A; Dieli F
Tuberculosis (Edinb); 2009 Jan; 89(1):91-4. PubMed ID: 18986840
[TBL] [Abstract][Full Text] [Related]
18. PGG-glucan, a leukocyte-specific immunostimulant, does not potentiate GVHD or allograft rejection.
Washburn WK; Otsu I; Gottschalk R; Monaco AP
J Surg Res; 1996 May; 62(2):179-83. PubMed ID: 8632636
[TBL] [Abstract][Full Text] [Related]
19. Complement function in mAb-mediated cancer immunotherapy.
Gelderman KA; Tomlinson S; Ross GD; Gorter A
Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
[No Abstract] [Full Text] [Related]
20. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
